Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
AbCellera entered a preclinical research collaboration and license agreement with Jazz Pharmaceuticals to discover next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and solid tumors. AbCellera is eligible to receive $56 million in upfront payments for the initial programs, with an additional $28 million due upon initiation of a third program, as well as up to $792 million per program in milestones and tiered royalties on net sales.
Key figures
- Royalties
- mid-single digits to low double-digits
- Upfront payment usd
- 56000000
- Potential milestones usd
- 792000000
- Potential additional upfront usd
- 28000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.